Press Releases 2017-09-13T20:17:34+00:00

Press Releases

With Ocrevus Uptake in Primary Progressive Multiple Sclerosis a Relative Lock, Genentech and US Neurologists are Increasingly Focused on Ocrevus Positioning in Relapsing Forms of Multiple Sclerosis

Swift uptake of Mylan’s generic glatiramer acetate 20mg and 40mg is being driven by perceptions of preferential payer coverage although a dispensed-as-written strategy for Teva’s Copaxone may be limiting greater conversion, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., December 7, 2017 /PRNewswire/ — Seven months post-launch, the clear majority of US neurologists (n=103) have initiated at least one patient on Genentech’s Ocrevus, with the brand share being boosted by uptake in both relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) patients. Reflecting the great unmet need for PPMS treatments and [...]

December 7, 2017|

Eli Lilly’s Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis’ Cosentyx

According to Spherix Global Insights’ RealTime Dynamix™: Psoriatic Arthritis quarterly series, US rheumatologists have become increasingly familiar with Taltz as a potential treatment for PsA and are primed to adopt the newest IL-17 agent into their PsA armamentarium. Download Report Overview EXTON, Pa., December 4, 2017 /PRNewswire/ — Eli Lilly’s IL-17 inhibitor, Taltz (ixekizumab), received FDA approval for the treatment of adults with active psoriatic arthritis (PsA) on December 1, 2017. The new indication for the brand will bring increased competition to a market that has been bustling with recent change via a series of line extensions (BMS’ Orencia and [...]

December 4, 2017|

US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt

According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings. Download Report Overview EXTON, Pa., Nov. 30, 2017 /PRNewswire/ -- The most recent release of RealTime Dynamix™: Atopic Dermatitis reveals steady uptake of the newest atopic dermatitis launches, Dupixent and Eucrisa. Both agents have consistently enjoyed substantial user- and patient-base gains quarter over quarter since launching, with the vast majority of collaborating dermatologists reporting current clinical experience. Furthermore, projected use [...]

November 30, 2017|

Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis

According to Spherix Global Insights' latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is largely comparable to that of Taltz's at a similar post-launch timeframe. Download Report Overview EXTON, Pa., Nov. 29, 2017 /PRNewswire/ -- At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, a figure on par with uptake of Taltz at a similar post-launch fielding time. Current users of the IL-23 inhibitor cite that they most commonly initiate patients on the brand due to their severity and the perceived efficacy that Tremfya may offer. Furthermore, over half [...]

November 29, 2017|

Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win

According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of alternative mechanism of action biologics such as Entyvio and Stelara as well as the slow, but growing, adoption of infliximab biosimilars in the IBD market Download Report Overview EXTON, Pa. Nov. 21, 2017 /PRNewswire/ — A survey of over 100 US gastroenterologists fielded in late October 2017 indicates that, in both the ulcerative colitis (UC) and Crohn’s Disease (CD) markets, the established TNF inhibitors, Remicade and AbbVie’s Humira, persistently dominate biologic market share. Alternative mechanism of action (MOA) biologics, Entyvio [...]

November 21, 2017|

Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US

EU5 adoption of Pfizer's Xeljanz and Eli Lilly's Olumiant has been largely limited to rheumatologists practicing in Germany, according to a recently released independent report by Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ -- Analysis of over 2,200 RA patients in the US and EU5 (France, Germany, Italy, Spain, and the United Kingdom) reveals clear differentiation in treatment patterns amongst rheumatoid arthritis (RA) patients who have recently switched brands. US rheumatologists (n=176) report that 28% of their biologic/JAK-treated RA patients switched brands in a given year, a figure significantly higher than the 23% switch rate [...]

November 21, 2017|